摘要
目的分析在下呼吸道感染患者治疗中,予以头孢哌酮舒巴坦钠联合左氧氟沙星联合干预的临床效果。方法选择2018年3月—2021年8月在该科接收的下呼吸道感染患者50例为研究对象,采取随机数表法将其均分为两组,使用单一药物左氧氟沙星干预的25例患者纳入对照组,使用头孢哌酮舒巴坦钠联合左氧氟沙星治疗的25例患者纳入观察组。对比两组患者在不同用药方案下的治疗效果、症状消失时间、住院时间、炎症因子水平及不良反应发生率。结果观察组治疗有效率为96.00%,高于对照组的68.00%,差异有统计学意义(χ^(2)=4.878,P<0.05);观察组发热、咳嗽、胸痛、肺部啰音消失时间及住院时间为(3.19±0.55)、(3.20±0.44)、(2.71±0.60)、(4.96±0.82)、(6.77±1.35)d,均短于对照组的(4.76±0.41)、(4.92±0.48)、(4.70±0.52)、(6.87±0.91)、(10.26±2.13)d,差异有统计学意义(t=11.443、13.207、12.532、7.796、6.920,P<0.05);治疗后,观察组的TNF-α、IL-6水平为(17.58±2.39)μg/L、(20.05±3.47)mg/L,均低于对照组的(22.37±4.15)μg/L、(28.55±5.46)mg/L,差异有统计学意义(t=5.001、6.569,P<0.05);观察组不良反应发生率为4.00%,与对照组的12.00%相比较差异无统计学意义(χ^(2)=0.272,P>0.05)。结论在下呼吸道感染患者治疗中,予以头孢哌酮舒巴坦钠联合左氧氟沙星联合干预效果显著,安全性高。
Objective To analyze the clinical effect of cefoperazone-sulbactam sodium Combined with levofloxacin in the treatment for patients with lower respiratory tract infection.Methods 50 patients with lower respiratory tract infection admitted to the department from March 2018 to August 2021 were selected as the study subjects.They were divided into two groups by random number table method.25 patients treated with levofloxacin only were in the control group.25 patients treated with cefoperazone-sulbactam sodium Combined with levofloxacin were in the observation group.The treatment effect,symptom disappearance time,hospital stay,inflammatory factor level and incidence of adverse reactions were compared between the two groups.Results The effective rate of treatment in the observation group was 96.00%which was higher than 68.00%of the control group,and the difference was statistically significant(χ^(2)=4.878,P<0.05).The time of fever,cough,chest pain,pulmonary rales disappearance,hospital stay in the observation group were(3.19±0.55)d,(3.20±0.44)d,(2.71±0.60)d,(4.96±0.82)d,(6.77±1.35)d,which were significantly shorter than(4.76±0.41)d,(4.92±0.48)d,(4.70±0.52)d,(6.87±0.91)d,(10.26±2.13)d of the control group,and the difference was statistically significant(t=11.443,13.207,12.532,7.796,6.920,P<0.05).After treatment,the levels of TNF-α,IL-6 of the observation group were(17.58±2.39)μg/L,(20.05±3.47)mg/L,which were significantly lower than(22.37±4.15)μg/L,(28.55±5.46)mg/L of the control group,and the difference was statistically significant(t=5.001,6.569,P<0.05).The incidence of adverse reactions of the observation group was 4.00%which had no statistically significant difference compared with 12.00%of the control group(χ^(2)=0.272,P>0.05).Conclusion Cefoperazone-sulbactam sodium combined with levofloxacin in the treatment for patients with lower respiratory tract infection has significant effect and high safety.
作者
李萌
LI Meng(Department of Emergency Medicine,Pizhou Traditional Chinese Medicine Hospital,Pizhou,Jiangsu Province,221300 China)
出处
《系统医学》
2022年第8期100-103,共4页
Systems Medicine
关键词
下呼吸道感染
头孢哌酮舒巴坦钠
左氧氟沙星
炎症因子
Lower respiratory tract infection
Cefoperazone-sulbactam sodium
Levofloxacin
Inflammatory factor
